Affiliate-supportedIndependent editorialWe never sell medicationSee how
Endocrinology · Type 2 Diabetes specialist · Clinical Reviewer
LinkedIn profileDr. Patel is a board-certified endocrinologist (American Board of Internal Medicine, Endocrinology Diabetes & Metabolism subspecialty) and Fellow of the American College of Endocrinology. Clinical focus is type 2 diabetes management with GLP-1 receptor agonists, cardiovascular risk reduction, and metabolic syndrome. Reviews all GLP1Zoom content on diabetes + cardiovascular topics. Affiliation: independent endocrinology practice; consulting clinical reviewer for GLP1Zoom (flat-fee compensation, not affiliate revenue).
14+ years of clinical practice
Residency: Cleveland Clinic — Endocrinology, Diabetes & Metabolism Fellowship 2013
Cleveland Clinic Endocrinology
Staff Endocrinologist
2013-2019
Mass General Brigham Diabetes Center
Attending Endocrinologist
2019-2024
Topics where Dr. Marcus Patel provides specialty review for GLP1Zoom editorial content.
Dr. Marcus Patel, MD, FACE is one of 5 specialists on the GLP1Zoom Medical Review Board. Reviewers are independently practicing clinicians compensated on a flat-fee basis for review time; they do not receive affiliate commissions or referral payments.
Independent Endocrinology Practice
Founding Physician
2024-present
Tirzepatide in the management of type 2 diabetes — a real-world cohort analysis
Diabetes Care · 2024
GLP-1 receptor agonists and cardiovascular outcomes — clinical considerations
Journal of the American College of Cardiology · 2023
The New York Times
How endocrinologists are deciding which GLP-1 to prescribe
WebMD
Mounjaro vs Ozempic — what the data really show